Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

"Side" effects: a misnomer

C R Joyce

    Journal of Medical Ethics
    |September 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    The term "side effects" may understate drug impacts. Collecting patient and physician data is crucial for identifying unintended drug effects and improving drug safety.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    What do patients want from medical research?

    Journal of the Royal Society of Medicine·2010
    Same author

    Missing inaction.

    Journal of the Royal Society of Medicine·2010
    Same author

    Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals.

    Journal of acquired immune deficiency syndromes (1999)·1999
    Same author

    Illustration of a method for selecting research grant applications.

    Alternative therapies in health and medicine·1997
    Same author

    Development of a direct weighting procedure for quality of life domains.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·1997
    Same author

    Use, misuse and abuse of questionnaires on quality of life.

    Patient education and counseling·1995
    Same journal

    Assisted dying and autonomy as an end in itself: a response to Donaldson.

    Journal of medical ethics·2026
    Same journal

    Ethics briefing.

    Journal of medical ethics·2026
    Same journal

    Medical ethics and categorisation.

    Journal of medical ethics·2026
    Same journal

    Suspension or prioritisation? Exploring the ethics of age-based rationing in adult ADHD services.

    Journal of medical ethics·2026
    Same journal

    Ethics of not knowing who we are talking to in qualitative research.

    Journal of medical ethics·2026
    Same journal

    Suicide is not a public health issue and perhaps very few things should be.

    Journal of medical ethics·2026
    See all related articles

    Area of Science:

    • Pharmacovigilance and Drug Safety
    • Clinical Pharmacology
    • Medical Ethics

    Background:

    • The term "side effects" inadequately describes severe adverse drug reactions, as exemplified by thalidomide's tragic outcomes.
    • Current pre-market clinical trials cannot fully anticipate or eliminate all adverse drug effects.
    • There is a need for improved communication channels regarding drug effects observed post-marketing.

    Purpose of the Study:

    • To advocate for replacing the term "side effects" with "additional effects" to better reflect drug impacts.
    • To emphasize the importance of systematic collection and evaluation of data from patients and physicians.
    • To propose mechanisms for reassessing drug safety based on real-world observations.

    Main Methods:

    • Literature review and commentary on existing drug safety reporting and evaluation practices.

    Related Experiment Videos

  • Analysis of the limitations of pre-market drug testing.
  • Discussion of physician and patient reporting of drug effects to manufacturers.

    • Main Results:

    • Existing terminology may minimize the significance of adverse drug events.
    • Effective post-marketing surveillance requires robust data collection from healthcare providers and patients.
    • Current regulatory bodies may lack the capacity for continuous drug reassessment.

    Conclusions:

    • A shift in terminology from "side effects" to "additional effects" is proposed to enhance the perception of drug risks.
    • Establishing a dedicated panel for reassessing drugs based on post-marketing data is recommended.
    • The medical necessity of a drug should be established prior to its manufacture and widespread prescription.